What is the criteria for smoldering myeloma?

To meet the definition of smoldering multiple myeloma, both of the following criteria must be met: Serum monoclonal protein (IgG or IgA) ≥30 g/L or urinary monoclonal protein ≥500 mg per 24 h and/or clonal bone marrow plasma cells 10–60% Absence of myeloma-defining events or amyloidosis.

How do you treat SMM?

If you’re at high risk for active multiple myeloma, your doctor may prescribe a chemotherapy drug, lenalidomide (Revlimid), and dexamethasone. These treatments may help you prevent complications and live longer. Immunotherapy. This new type of treatment for smoldering multiple myeloma is in clinical trials.

What is SMM disease?

Abstract. Smoldering multiple myeloma (SMM) is an asymptomatic clonal plasma cell disorder. SMM is distinguished from monoclonal gammopathy of undetermined significance by a much higher risk of progression to multiple myeloma (MM).

What is asymptomatic myeloma?

Smouldering myeloma (also sometimes known as asymptomatic myeloma) is an early form of myeloma which usually progresses to active myeloma, but at a slow rate. In smouldering myeloma abnormal cells can be detected in the bone marrow, and abnormal protein can be detected in the blood and/or urine.

Can multiple myeloma be asymptomatic?

Smoldering (asymptomatic) multiple myeloma is an asymptomatic plasma-cell proliferative disorder associated with a high risk of progression to symptomatic multiple myeloma or amyloidosis. Prognostic factors for the progression and outcome of this disease are unclear.

What is high risk smoldering myeloma?

Smoldering multiple myeloma (SMM) is an asymptomatic plasma cell dyscrasia with a high propensity to progress to symptomatic myeloma (MM). It meets all the diagnostic criteria for MM, but without lytic bone disease, anemia, renal failure, or hypercalcemia (CRAB symptoms).